50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Retail investors buy Novo dip after disappointing weight-loss drug data

Published 12/24/2024, 09:38 AM
Updated 12/24/2024, 09:40 AM
© Reuters. FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little//File Photo
LLY
-
NVO
-

By Bhanvi Satija

(Reuters) - U.S. retail investor fund flows into Novo Nordisk (NYSE:NVO) surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda (NASDAQ:VNDA) Research.

Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo's experimental drug, CagriSema, helped patients cut 22.7% of their weight—short of the anticipated 25%.

Novo competes with U.S. rival Eli Lilly (NYSE:LLY) in the burgeoning market for weight-loss treatments, which is projected to exceed $150 billion in revenue within the next decade.

"Retail investors love to buy dips, especially in popular stocks..and do so, until that doesn't work anymore," said Marco Iachini, senior vice president of research at Vanda.

Shares of Novo Nordisk dropped 27% on Friday, erasing over $100 billion in market value. Its U.S.-listed shares tumbled 21% to $81.50, their lowest level since August 2023.

"Right now Novo only dipped below S&P 500 performance for the first time in 2 years so, probably too early to see them (retail investors) give up on their buy-the dip-bias," he said. The retail flows on Friday likely provided an exit for institutional investors.

Funds from retail investors touched a one-day high of $23.5 million on March 7, data from Vanda shows, after Novo's amycretin drug helped obese patients cut 13% of their weight in a study.

The success of Novo’s Wegovy and Lilly’s Zepbound weight-loss drugs has revived retail interest in the healthcare sector.

"With their GLP-1 product in the market and Eli Lilly being a lot on the news...a lot of retail investors know about Lilly," said Sel Hardy, vice president of equity research at CFRA.

She suggested that a sell-off, like Lilly's stock dip in October, and mid-November, could provide “an attractive entry point” for retail investors

Net retail flows into Lilly have outpaced Novo in the second half of 2024, according to Vanda.

© Reuters. FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little//File Photo

For Lilly, net retail purchases peaked in August after its weight-loss drug sales surpassed $1 billion for the quarter, prompting a $3 billion forecast increase.

However, retail activity in these stocks lags behind tech giants such as Nvidia (NASDAQ:NVDA) and Tesla (NASDAQ:TSLA), where activity often reaches the high teens.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.